With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB ... pipeline of drugs including TECFIDERA, VUMERITY, AVONEX, SPINRAZA, SKYCLARYS, and QALSODY.

Biogen Inc. has a 12 month low of $128.51 and ... The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy ...

The suit claimed that Biogen paid millions of dollars to doctors in the form of speaker honoraria, training fees, consulting fees, and meals to induce them to prescribe the MS drugs Avonex ...

Biogen Inc. (NASDAQ:BIIB ... including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. It also markets SPINRAZA to treat SMA, SKYCLARYS for the treatment of Friedreich’s Ataxia ...

Biogen Inc. has a 12-month low of $128.51 and ... The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...

Biogen's efforts to replenish its multiple sclerosis ... with its current MS drugs like Tecfidera (dimethyl fumarate), Avonex (interferon beta-1a), and Tysabri (natalizumab).

The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...